Clinical Trial Update: 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide [Phase 3]

View source ↗

Summary

This ClinicalTrials.gov update reports the completion of a Phase 3 study evaluating intranasal esketamine plus standard of care for rapid reduction of symptoms …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Spravato (esketamine nasal spray) (Esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2020-10-29